

# Integration and Centralization of Clinical Research Operations across Campuses to Maximize Efficiency and Oversight

Tooba Imtiaz<sup>1</sup>, Brittany McGough<sup>1</sup>, Melanie Huber<sup>1</sup>, Ankeeta Joshi<sup>1</sup>, Janice Mehnert<sup>1,2</sup>, Douglas K Marks<sup>1,3</sup>

<sup>1</sup>Laura and Isaac Perlmutter Cancer Center; <sup>2</sup>NYU Grossman School of Medicine, New York City, NY, <sup>3</sup>NYU Long Island School of Medicine, Mineola, NY



## INTRODUCTION

- NYU Langone Health merged with Winthrop Hospital in 2019. After the institutional merger, the Perlmutter Cancer Center (PCC) and the Clinical Trials Office (CTO) was integrated across both Manhattan and Long Island Campuses. A strategic plan was required to standardize operation procedures and increase scale of CTO operations in Long Island to expand trial access for patients.
- Disease management groups (DMGs) are multi-disciplinary teams focusing on specific disease sites, and they oversee individual oncology clinical research portfolios, and they were also integrated across campuses.


## GOALS

- Standardize operations across PCC campuses
- Increase operational efficiency through centralization of resources to activate multi-site trials
- Integrate Disease Management Groups
- Strategize to identify goals, opportunities and address barriers across campuses

## SUMMARY AND FUTURE DIRECTIONS

**Centralization improved communication, adherence to workflows, and accruals with a mean annual increase of 35% observed from 2021 to 2023.**

**Future directions include expanding access to trials of increasing complexity throughout PCC network locations.**



*The authors wish to acknowledge our clinical trial patients who inspire us everyday, and through their participation, will improve treatment options for future patients.*

## METHODS

Initial step was to integrate DMGs across the campuses and to evaluate trial feasibility for each PCC campus based on patient needs.

- Leadership teams from all PCC campuses joined strategic meetings to identify goals, opportunities for expansion, and improve barriers to trial participation.
- Leadership collaborated with sponsors to address and resolve logistics for trials offered at PCC and to advocate for multi-site activations.
- With multi-site trials, financial operations such as billing grids and budget negotiations were centralized.
- Integrated pre and post activation regulatory teams for all DMGs across campuses so that ISF management and portfolio oversight was overseen by one team.
- Integrated data coordinators so that cross coverage expanded within DMGs.

## OUTCOMES

With integrated data and regulatory teams, there was more cross coverage for tasks.

- The primary factor contributing to the accrual increase was higher trial offerings within each DMG at the Mineola campus including the expansion of a Phase I program.
- There was an increase in portfolio size, decrease in study activation time, efficiency of resources and most importantly the growth of accruals at PCC campuses.
- Integration of resources and centralization of operations has led to sponsors agreeing to multi-site activations and LI and Manhattan have 1/3 of the trials open at both locations.
- **Long Island Mineola campus noted a 47% accrual increase from 2021 to 2022 and another 23 % increase from 2022-2023.**

Contact



Perlmutter  
Cancer Center

NCI Comprehensive  
Cancer Center